Exascale Labs director reports no holdings

Exascale Labs Holdings Inc. (XLAB) director Shin Jaeyoung has filed an initial Form 3 reporting status as a director of the company.

Rhea-AI Filing Summary

Exascale Labs Holdings Inc. (XLAB) director Shin Jaeyoung has filed an initial Form 3 reporting status as a director of the company. The filing lists no equity transactions and no reportable holdings or derivative positions as of the reporting date.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Net shares bought or sold: 0 shares +1 more

4 metrics

Buy transactions 0 transactions Number of purchase transactions reported in the Form 3 transaction summary

Sell transactions 0 transactions Number of sale transactions reported in the Form 3 transaction summary

Net shares bought or sold 0 shares Net buy/sell shares in the Form 3 transaction summary

Holding entries 0 positions Reported non-derivative and derivative holding entries for Shin Jaeyoung

FAQ

What does the Form 3 filed for XLAB by Shin Jaeyoung report?

The Form 3 reports that Shin Jaeyoung is a director of Exascale Labs Holdings Inc. and, as of the filing, shows no reportable holdings of the company’s securities and no equity transactions.

Does the XLAB Form 3 show any share purchases or sales by Shin Jaeyoung?

No. The Form 3 transaction summary shows 0 buy transactions, 0 sell transactions, and 0 net shares bought or sold, indicating no reported trading activity in Exascale Labs Holdings Inc. securities.

What ownership position does the XLAB Form 3 disclose for Shin Jaeyoung?

The filing’s summary indicates 0 holding entries and no derivative positions, so it does not disclose any reportable direct or indirect ownership of Exascale Labs Holdings Inc. securities as of the reporting date.

Is there any Rule 10b5-1 trading plan reported in the XLAB Form 3?

No. The Form 3 data do not indicate that trades were made under a Rule 10b5-1 trading plan, and there are no reported transactions in the filing.

What role does Shin Jaeyoung have at Exascale Labs Holdings Inc. according to the Form 3?

According to the Form 3, Shin Jaeyoung is a director of Exascale Labs Holdings Inc. and is not reported as an officer or a ten percent owner of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 12:39 PM Accepted by SEC EDGAR 09/08/2026 - 12:38 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shin Jaeyoung

(Last) (First) (Middle)

820 GESSNER ROAD, SUITE 332

(Street)

HOUSTON, TEXAS 77024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/27/2026

3. Issuer Name and Ticker or Trading Symbol
Exascale Labs Holdings Inc. [ XLAB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jaeyoung Shin	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)